141 related articles for article (PubMed ID: 7540561)
1. CYFRA 21-1 as a tumour marker for bronchogenic carcinoma.
Rapellino M; Niklinski J; Pecchio F; Furman M; Baldi S; Chyczewski L; Ruffini E; Chyczewska E
Eur Respir J; 1995 Mar; 8(3):407-10. PubMed ID: 7540561
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
3. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
4. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer.
Niklinski J; Furman M; Chyczewska E; Chyczewski L; Rogowski F; Laudanski J
Eur Respir J; 1995 Feb; 8(2):291-4. PubMed ID: 7538933
[TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment.
Sugama Y; Kitamura S; Kawai T; Ohkubo A; Hasegawa S; Kuriyama T; Kato H; Fukuoka M; Ohkawa J
Jpn J Cancer Res; 1994 Nov; 85(11):1178-84. PubMed ID: 7530241
[TBL] [Abstract][Full Text] [Related]
7. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases.
Nakayama M; Satoh H; Ishikawa H; Fujiwara M; Kamma H; Ohtsuka M; Sekizawa K
Chest; 2003 Jun; 123(6):2001-6. PubMed ID: 12796181
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin fragment 19 (CYFRA 21-1) as a tumor marker in non-small cell lung cancer.
Huang MS; Jong SB; Lin MS; Chong IW; Tsai MS; Lin HC; Hwang JJ
Kaohsiung J Med Sci; 1996 Feb; 12(2):62-8. PubMed ID: 8709175
[TBL] [Abstract][Full Text] [Related]
11. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group.
Rastel D; Ramaioli A; Cornillie F; Thirion B
Eur J Cancer; 1994; 30A(5):601-6. PubMed ID: 7521651
[TBL] [Abstract][Full Text] [Related]
12. [Basic and clinical studies on serum cytokeratin 19 fragment assay using Centocor CYFRA 21-1 kit in patients with lung cancer].
Hamase A; Sugimoto Y; Maeda M; Kitani H; Fukuchi M
Kaku Igaku; 1994 Aug; 31(8):969-76. PubMed ID: 7523748
[TBL] [Abstract][Full Text] [Related]
13. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
[TBL] [Abstract][Full Text] [Related]
15. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
16. A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma.
Kim YC; Park KO; Choi IS; Kim HJ; Lim SC; Bom HS
Korean J Intern Med; 1996 Jan; 11(1):50-7. PubMed ID: 8882476
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.
Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB
Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA
Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]